Circulating Tumour Cells and prostate cancer outcome II

According to the Canadian Cancer Society, an estimated 26,500 men will be diagnosed with
prostate cancer in 2012 and 4,000 will die of it. New approaches are required to predict
clinical outcome and personalized management of patients. Drs. Mal and Cayre will combine
their two newly developed technologies and work towards obtaining a new solid biomarker
that enables the assessment of a patient’s clinical outcome from the start. With the use of
special filters, circulating tumour cells (CTC) will be isolated from prostate cancer patients’
blood. These cells are characterized using three-dimensional (3D) imaging of telomeres (the
ends of chromosomes) in the cells’ nuclei. This will be the first time these new technologies
are combined to investigate the link between CTCs, their 3D telomeric profiles and clinical
outcome of prostate cancer. A much better understanding and personalized management of
prostate cancer, which is a major goal of CancerCare Manitoba will be achieved by this
project.

Faculty Supervisor:

Sabine Mai

Student:

Partner:

Cancer Care (Manitoba);Carl Zeiss Canada

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology

University:

University of Manitoba

Program: